Impact of Genetic Variation in OATP Transporters to Drug Disposition and Response

Lazarou, 1998, Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies, JAMA, 279, 1200, 10.1001/jama.279.15.1200

Severino, 2004, Adverse drug reactions: role of pharmacogenomics, Pharmacol. Res., 49, 363, 10.1016/j.phrs.2003.05.003

Scott, 2011, Personalizing medicine with clinical pharmacogenetics, Genet. Med., 13, 987, 10.1097/GIM.0b013e318238b38c

Spear, 2001, Clinical application of pharmacogenetics, Trends Mol. Med., 7, 201, 10.1016/S1471-4914(01)01986-4

Meyer, 2004, Pharmacogenetics - five decades of therapeutic lessons from genetic diversity, Nat. Rev. Genet., 5, 669, 10.1038/nrg1428

Wei, 2012, Pharmacogenomics of adverse drug reactions: implementing personalized medicine, Hum. Mol. Genet., 10.1093/hmg/dds341

Wilkinson, 2005, Drug metabolism and variability among patients in drug response, N. Engl. J. Med., 352, 2211, 10.1056/NEJMra032424

DeGorter, 2012, Drug transporters in drug efficacy and toxicity, Annu. Rev. Pharmacol. Toxicol., 52, 249, 10.1146/annurev-pharmtox-010611-134529

Ho, 2005, Transporters and drug therapy: implications for drug disposition and disease, Clin. Pharmacol. Ther., 78, 260, 10.1016/j.clpt.2005.05.011

Lee, 2010, Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents, Anticancer Agents Med. Chem., 10, 583, 10.2174/187152010794474019

Giacomini, 2010, Membrane transporters in drug development, Nat. Rev. Drug Discov., 9, 215, 10.1038/nrd3028

Hagenbuch, 2003, The superfamily of organic anion transporting polypeptides, Biochim. Biophys. Acta, 1609, 1, 10.1016/S0005-2736(02)00633-8

Konig, 2000, A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane, Am. J. Physiol. Gastrointest. Liver Physiol., 278, G156, 10.1152/ajpgi.2000.278.1.G156

Kullak-Ublick, 2001, Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver, Gastroenterology, 120, 525, 10.1053/gast.2001.21176

Tamai, 2000, Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family, Biochem. Biophys. Res. Commun., 273, 251, 10.1006/bbrc.2000.2922

Kullak-Ublick, 1995, Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver, Gastroenterology, 109, 1274, 10.1016/0016-5085(95)90588-X

Niemi, 2007, Role of OATP transporters in the disposition of drugs, Pharmacogenomics, 8, 787, 10.2217/14622416.8.7.787

Kalliokoski, 2009, Impact of OATP transporters on pharmacokinetics, Br. J. Pharmacol., 158, 693, 10.1111/j.1476-5381.2009.00430.x

Abe, 1999, Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1, J. Biol. Chem., 274, 17159, 10.1074/jbc.274.24.17159

Tirona, 2001, Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans, J. Biol. Chem., 276, 35669, 10.1074/jbc.M103792200

Kameyama, 2005, Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells, Pharmacogenet. Genomics, 15, 513, 10.1097/01.fpc.0000170913.73780.5f

Michalski, 2002, A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter, J. Biol. Chem., 277, 43058, 10.1074/jbc.M207735200

Ho, 2006, Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics, Gastroenterology, 130, 1793, 10.1053/j.gastro.2006.02.034

Oswald, 2008, Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1, Pharmacogenet. Genomics, 18, 559, 10.1097/FPC.0b013e3282fe9a2c

Nozawa, 2005, Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms, Drug Metab. Dispos., 33, 434, 10.1124/dmd.104.001909

Tirona, 2003, Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation, J. Pharmacol. Exp. Ther., 304, 223, 10.1124/jpet.102.043026

Katz, 2006, Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics, Clin. Pharmacol. Ther., 79, 186, 10.1016/j.clpt.2005.11.003

Nozawa, 2002, Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis, J. Pharmacol. Exp. Ther., 302, 804, 10.1124/jpet.302.2.804

Iwai, 2004, Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C), Pharmacogenetics, 14, 749, 10.1097/00008571-200411000-00006

Niemi, 2004, High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1), Pharmacogenetics, 14, 429, 10.1097/01.fpc.0000114750.08559.32

Furihata, 2009, Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy, Pharmacogenomics J., 9, 185, 10.1038/tpj.2009.3

Neuvonen, 1998, Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole, Clin. Pharmacol. Ther., 63, 332, 10.1016/S0009-9236(98)90165-5

Hsiang, 1999, A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters, J. Biol. Chem., 274, 37161, 10.1074/jbc.274.52.37161

Nishizato, 2003, Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics, Clin. Pharmacol. Ther., 73, 554, 10.1016/S0009-9236(03)00060-2

Igel, 2006, Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin, Clin. Pharmacol. Ther., 79, 419, 10.1016/j.clpt.2006.01.010

Pasanen, 2007, Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin, Clin. Pharmacol. Ther., 82, 726, 10.1038/sj.clpt.6100220

Lee, 2005, Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment, Clin. Pharmacol. Ther., 78, 330, 10.1016/j.clpt.2005.06.013

Pasanen, 2006, SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid, Pharmacogenet. Genomics, 16, 873, 10.1097/01.fpc.0000230416.82349.90

Mwinyi, 2004, Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics, Clin. Pharmacol. Ther., 75, 415, 10.1016/j.clpt.2003.12.016

Maeda, 2006, Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril, Clin. Pharmacol. Ther., 79, 427, 10.1016/j.clpt.2006.01.011

Choi, 2008, Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans, Clin. Pharmacol. Ther., 83, 251, 10.1038/sj.clpt.6100267

Hedman, 2006, Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes, Br. J. Clin. Pharmacol., 61, 706, 10.1111/j.1365-2125.2006.02643.x

Niemi, 2005, Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17, Pharmacogenet. Genomics, 15, 303, 10.1097/01213011-200505000-00005

Gerloff, 2006, Influence of the SLCO1B1*1b and *5 haplotypes on pravastatin's cholesterol lowering capabilities and basal sterol serum levels, Naunyn Schmiedebergs Arch. Pharmacol., 373, 45, 10.1007/s00210-006-0053-6

Tachibana-Iimori, 2004, Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors, Drug Metab. Pharmacokinet., 19, 375, 10.2133/dmpk.19.375

Generaux, 2011, Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins, Xenobiotica, 41, 639, 10.3109/00498254.2011.562566

Link, 2008, SLCO1B1 variants and statin-induced myopathy—a genomewide study, N. Engl. J. Med., 359, 789799

Voora, 2009, The SLCO1B1*5 genetic variant is associated with statin-induced side effects, J. Am. Coll. Cardiol., 54, 1609, 10.1016/j.jacc.2009.04.053

Donnelly, 2011, Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study, Clin. Pharmacol. Ther., 89, 210, 10.1038/clpt.2010.255

Brunham, 2012, Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin, Pharmacogenomics J., 12, 233, 10.1038/tpj.2010.92

Niemi, 2011, Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake, Pharmacol. Rev., 63, 157181, 10.1124/pr.110.002857

Niemi, 2005, Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics, Clin. Pharmacol. Ther., 77, 468, 10.1016/j.clpt.2005.01.018

Kalliokoski, 2008, The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range, Br. J. Clin. Pharmacol., 66, 818, 10.1111/j.1365-2125.2008.03287.x

Kalliokoski, 2008, Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide, Pharmacogenet. Genomics, 18, 937, 10.1097/FPC.0b013e32830d733e

Kalliokoski, 2008, Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide, J. Clin. Pharmacol., 48, 311, 10.1177/0091270007311569

Zhang, 2006, Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide, Br. J. Clin. Pharmacol., 62, 567, 10.1111/j.1365-2125.2006.02686.x

Aquilante, 2008, Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers, Hum. Genomics, 3, 7, 10.1186/1479-7364-3-1-7

Trevino, 2009, Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects, J. Clin. Oncol., 27, 5972, 10.1200/JCO.2008.20.4156

Li, 2012, SLCO1B1 *15 haplotype is associated with rifampin-induced liver injury, Mol. Med. Rep., 6, 75

Picard, 2010, The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics, Clin. Pharmacol. Ther., 87, 100, 10.1038/clpt.2009.205

Geng, 2012, The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals, Clin. Chim. Acta, 413, 683, 10.1016/j.cca.2011.12.003

Michelon, 2010, SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients, Pharmacogenomics, 11, 1703, 10.2217/pgs.10.132

Niemi, 2005, Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1), Br. J. Clin. Pharmacol., 59, 602, 10.1111/j.1365-2125.2005.02354.x

Han, 2008, Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer, Lung Cancer, 59, 69, 10.1016/j.lungcan.2007.07.019

Hartkoorn, 2010, HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms, Pharmacogenet. Genomics, 20, 112, 10.1097/FPC.0b013e328335b02d

Suwannakul, 2008, Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism, J. Hum. Genet., 53, 899, 10.1007/s10038-008-0324-9

Vormfelde, 2008, The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics, Clin. Pharmacol. Ther., 83, 815, 10.1038/sj.clpt.6100404

Tian, 2011, Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics ofenalapril in healthy Chinese adult men, Clin. Ther., 33, 655, 10.1016/j.clinthera.2011.04.018

Iida, 2001, Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH: ubiquinone oxidoreductase flavoproteins, J. Hum. Genet., 46, 668, 10.1007/s100380170019

Letschert, 2004, Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8), Pharmacogenetics, 14, 441, 10.1097/01.fpc.0000114744.08559.92

Smith, 2005, Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel, Cancer Biol. Ther., 4, 815, 10.4161/cbt.4.8.1867

Chae, 2012, Functional consequences of genetic variations in the human organic anion transporting polypeptide 1B3 (OATP1B3) in the Korean population, J. Pharm. Sci., 101, 1302, 10.1002/jps.23005

Hamada, 2008, Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer, Clin. Cancer Res., 14, 3312, 10.1158/1078-0432.CCR-07-4118

Schwarz, 2011, Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity, Pharmacogenet. Genomics, 21, 103, 10.1097/FPC.0b013e328342f5b1

Smith, 2007, Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics, Clin. Pharmacol. Ther., 81, 76, 10.1038/sj.clpt.6100011

Chew, 2011, The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients, Cancer Chemother. Pharmacol., 67, 1471, 10.1007/s00280-011-1625-9

Baker, 2009, Pharmacogenetic pathway analysis of docetaxel elimination, Clin. Pharmacol. Ther., 85, 155, 10.1038/clpt.2008.95

Kiyotani, 2008, Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia, Cancer Sci., 99, 967, 10.1111/j.1349-7006.2008.00765.x

Yamada, 2011, The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers, Pharmacogenet. Genomics, 21, 523, 10.1097/FPC.0b013e3283482502

Endo, 2012, Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure. J. Hum. Genet., 57, 531, 10.1038/jhg.2012.63

Miura, 2007, Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients, Eur. J. Clin. Pharmacol., 63, 1161, 10.1007/s00228-007-0380-7

Yamakawa, 2011, Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia, Ther. DrugMonit., 33, 244

Konig, 2000, Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide, J. Biol. Chem., 275, 23161, 10.1074/jbc.M001448200

Nozawa, 2004, Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human, J. Pharmacol. Exp. Ther., 308, 438, 10.1124/jpet.103.060194

Imanaga, 2011, The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans, Pharmacogenet. Genomics, 21, 84, 10.1097/FPC.0b013e32834300cc

Ieiri, 2012, Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose, J. Clin. Pharmacol., 52, 1078, 10.1177/0091270011408612

Akamine, 2010, Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers, Xenobiotica, 40, 782789, 10.3109/00498254.2010.515318

Mougey, 2009, Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response, Pharmacogenet. Genomics, 19, 129, 10.1097/FPC.0b013e32831bd98c

Rebello, 2012, Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects, Eur. J. Clin. Pharmacol., 68, 697, 10.1007/s00228-011-1167-4

Knauer, 2010, Human skeletal muscle drug transporters determine local exposure and toxicity of statins, Circ. Res., 106, 297, 10.1161/CIRCRESAHA.109.203596

Franke, 2009, Pharmacogenetics of the organic anion transporting polypeptide 1A2, Pharmacogenomics, 10, 339, 10.2217/14622416.10.3.339

Meier, 2007, Regional distribution of solute carrier mRNA expression along the human intestinal tract, Drug Metab. Dispos., 35, 590, 10.1124/dmd.106.013342

Gao, 2000, Organic anion-transporting polypeptides mediate transport of opioid peptides across blood–brain barrier, J. Pharmacol. Exp. Ther., 294, 73

Lee, 2005, Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry, J. Biol. Chem., 280, 9610, 10.1074/jbc.M411092200

Badagnani, 2006, Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants, J. Pharmacol. Exp. Ther., 318, 521, 10.1124/jpet.106.104364

Eechoute, 2011, Environmental and genetic factors affecting transport of imatinib by OATP1A2, Clin. Pharmacol. Ther., 89, 816, 10.1038/clpt.2011.42

Yamakawa, 2011, Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia, Clin. Pharmacol. Ther., 90, 157, 10.1038/clpt.2011.102

Angelini, 2012, Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy, Haematologica

Svoboda, 2011, Organic anion transporting polypeptides (OATPs): regulation of expression and function, Curr. Drug Metab., 12, 139, 10.2174/138920011795016863

Nakakariya, 2008, Identification and species similarity of OATP transporters responsible for hepatic uptake of beta-lactam antibiotics, Drug Metab. Pharmacokinet., 23, 347, 10.2133/dmpk.23.347

Oostendorp, 2009, Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors, Drug Metab. Dispos., 37, 917, 10.1124/dmd.108.024901

Ni, 2010, Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition, PLoS ONE, 5, 10.1371/journal.pone.0013792

Nozawa, 2004, Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity, Drug Metab. Dispos., 32, 291, 10.1124/dmd.32.3.291

Matsushima, 2008, Involvement of multiple efflux transporters in hepatic disposition of fexofenadine, Mol. Pharmacol., 73, 1474, 10.1124/mol.107.041459

Treiber, 2007, Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil, Drug Metab. Dispos., 35, 1400, 10.1124/dmd.106.013615

Liu, 2006, Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers, J. Pharmacol. Exp. Ther., 318, 395, 10.1124/jpet.106.103390

Nakagomi-Hagihara, 2006, OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker, Drug Metab. Dispos., 34, 862, 10.1124/dmd.105.008888

Yamashiro, 2006, Involvement of transporters in the hepatic uptake and biliary excretion ofvalsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans, Drug Metab. Dispos., 34, 1247, 10.1124/dmd.105.008938

Werner, 2010, Gender is an important determinant of the disposition of the loop diuretic torasemide, J. Clin. Pharmacol., 50, 160, 10.1177/0091270009337514

Sandhu, 2005, Hepatic uptake of the novel antifungal agent caspofungin, Drug Metab. Dispos., 33, 676, 10.1124/dmd.104.003244

Shitara, 2004, J. Pharmacol. Exp. Ther., 311, 228, 10.1124/jpet.104.068536

Kopplow, 2005, Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells, Mol. Pharmacol., 68, 1031, 10.1124/mol.105.014605

Neuvonen, 2006, Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance, Clin. Pharmacol. Ther., 80, 565, 10.1016/j.clpt.2006.09.003

Hirano, 2004, Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans, J. Pharmacol. Exp. Ther., 311, 139, 10.1124/jpet.104.068056

Deng, 2008, The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15, Pharmacogenet. Genomics, 18, 424, 10.1097/FPC.0b013e3282fb02a3

Simonson, 2004, Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine, Clin. Pharmacol. Ther., 76, 167, 10.1016/j.clpt.2004.03.010

Vavricka, 2002, Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver, Hepatology, 36, 164, 10.1053/jhep.2002.34133

Hu, 2008, Interaction of imatinib with human organic ion carriers, Clin. Cancer Res., 14, 3141, 10.1158/1078-0432.CCR-07-4913

Abe, 2001, Molecular identification of organic anion transporter oatp/LST family, Tanpakushitsu Kakusan Koso, 46, 612

Yamaguchi, 2008, Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes, Cancer Lett., 260, 163, 10.1016/j.canlet.2007.10.040

Shimizu, 2005, Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans, Drug Metab. Dispos., 33, 1477, 10.1124/dmd.105.004622

Ishiguro, 2005, Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans, Drug Metab. Dispos., 34, 1109, 10.1124/dmd.105.009175

Seithel, 2007, The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3, Drug Metab. Dispos., 35, 779, 10.1124/dmd.106.014407

Tamai, 2001, Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C, Pharm. Res., 18, 1262, 10.1023/A:1013077609227

Grube, 2006, Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart, Clin. Pharmacol. Ther., 80, 607, 10.1016/j.clpt.2006.09.010

van Montfoort, 1999, Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1, J. Pharmacol. Exp. Ther., 290, 153

Franke, 2008, Influence of solute carriers on the pharmacokinetics of CYP3A4 probes, Clin. Pharmacol. Ther., 84, 704, 10.1038/clpt.2008.94

Kullak-Ublick, 1997, Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas, Gastroenterology, 113, 1295, 10.1053/gast.1997.v113.pm9322525

Bossuyt, 1996, Multispecific amphipathic substrate transport by an organic anion transporter of human liver, J. Hepatol., 25, 733, 10.1016/S0168-8278(96)80246-7

Su, 2004, Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells, Mol. Pharm., 1, 49, 10.1021/mp0340136

Fujino, 2005, Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase, J. Pharm. Pharmacol., 57, 1305, 10.1211/jpp.57.10.0009

Elens, 2007, 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation, Pharmacogenet. Genomics, 17, 873, 10.1097/FPC.0b013e3282e9a533

Bernsdorf, 2006, Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms, Br. J. Clin. Pharmacol., 61, 440, 10.1111/j.1365-2125.2006.02599.x

Lee, 2010, Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects, Int. J. Clin. Pharmacol. Ther., 48, 36, 10.5414/CPP48036

Niemi, 2006, SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin, Clin. Pharmacol. Ther., 80, 356, 10.1016/j.clpt.2006.06.010

Ho, 2007, Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants, Pharmacogenet. Genomics, 17, 647, 10.1097/FPC.0b013e3280ef698f

Zhang, 2006, SLCO1B1 521T⟶C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients, Br. J. Clin. Pharmacol., 64, 346, 10.1111/j.1365-2125.2007.02892.x

Kalliokoski, 2008, No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone, Br. J. Clin. Pharmacol., 65, 78, 10.1111/j.1365-2125.2007.02986.x

Xiang, 2006, Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients, Pharmacogenet. Genomics, 16, 683, 10.1097/01.fpc.0000230420.05221.71

Chung, 2005, Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers, Clin. Pharmacol. Ther., 78, 342, 10.1016/j.clpt.2005.07.003

Ieiri, 2007, SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers, Clin. Pharmacol. Ther., 82, 541, 10.1038/sj.clpt.6100190

Choi, 2012, Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin, Xenobiotica, 42, 496, 10.3109/00498254.2011.632030

Takane, 2006, Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy, J. Hum. Genet., 51, 822, 10.1007/s10038-006-0025-1

Couvert, 2008, Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy, Pharmacogenomics, 9, 1217, 10.2217/14622416.9.9.1217

Morimoto, 2004, A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy, Drug Metab. Pharmacokinet., 19, 453, 10.2133/dmpk.19.453